Provided by Tiger Trade Technology Pte. Ltd.

IN8bio, Inc.

1.28
+0.07005.79%
Post-market: 1.280.00000.00%19:30 EDT
Volume:105.89K
Turnover:131.95K
Market Cap:12.60M
PE:-0.68
High:1.30
Open:1.23
Low:1.18
Close:1.21
52wk High:2.73
52wk Low:0.8800
Shares:9.85M
Float Shares:6.26M
Volume Ratio:2.26
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8935
EPS(LYR):-4.4441
ROE:-111.11%
ROA:-58.37%
PB:0.69
PE(LYR):-0.29

Loading ...

IN8bio launches at-the-market equity program with JonesTrading, 3% sales commission

Reuters
·
Jun 01

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Syndax Pharmaceuticals (SNDX) and Olema Pharmaceuticals (OLMA)

TIPRANKS
·
May 22

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

GlobeNewswire
·
May 14

Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD), IN8bio (INAB) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
May 11

IN8bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

IN8bio Reports Q1 2026 Results and Shareholder Votes

TIPRANKS
·
May 08

IN8bio Q1 EPS $(0.26) Beats $(0.69) Estimate

Benzinga Earnings
·
May 08

IN8bio Q1 net loss narrows as R&D expenses fall

Reuters
·
May 08

IN8bio Q1 Basic EPS USD -0.26

THOMSON REUTERS
·
May 08

IN8bio Q1 Operating Income USD -5.09 Million

THOMSON REUTERS
·
May 08

Press Release: IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

Dow Jones
·
May 08

IN8bio Inc expected to post a loss of 69 cents a share - Earnings Preview

Reuters
·
May 07

IN8bio presents Phase I INB-200 glioblastoma study data at ASCO 2026

Reuters
·
May 06

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

GlobeNewswire
·
May 06

IN8bio Inc expected to post a loss of 69 cents a share - Earnings Preview

Reuters
·
Apr 30

IN8bio grants 11,800 inducement stock options to new hires under Nasdaq rule

Reuters
·
Apr 04

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 04

IN8bio announces 2026 annual stockholders meeting; FY2025 audit fees rise to $399,889

Reuters
·
Mar 27

IN8BIO Inc. publishes corporate presentation on gamma-delta T cell therapies in oncology and autoimmune diseases

Reuters
·
Mar 17

IN8bio Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 13